Related references
Note: Only part of the references are listed.Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes
J. Talbot et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
Fred Cohen et al.
PAIN MEDICINE (2021)
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew M. Blumenfeld et al.
PAIN AND THERAPY (2021)
Seymour Diamond: A Tribute to a Giant in the Headache Field In Memoriam
Vincent T. Martin et al.
HEADACHE (2020)
Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review
Tianwei She et al.
MEDICINE (2020)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
Rami Burstein et al.
HEADACHE (2020)
OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients
Ho-Tin Wong et al.
JOURNAL OF HEADACHE AND PAIN (2020)
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
Fayyaz Ahmed et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
Paul K. Winner et al.
DRUG SAFETY (2019)
Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine
Clare P. Herd et al.
BMJ OPEN (2019)
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
John F. Rothrock et al.
HEADACHE (2019)
Identifying and managing refractory migraine: barriers and opportunities?
Linda D'Antona et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Central Effects of Botulinum NeurotoxinEvidence from Human Studies
David Weise et al.
TOXINS (2019)
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal
A. P. Andreou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
A Phase-by-Phase Review of Migraine Pathophysiology
David W. Dodick
HEADACHE (2018)
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Andrew M. Blumenfeld et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers
Koyel J. Ghosal et al.
PLOS ONE (2018)
The binding of botulinum neurotoxins to different peripheral neurons
O. Rossetto
TOXICON (2018)
OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial
Theodore Wein et al.
PM&R (2018)
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
Lars Bendtsen et al.
JOURNAL OF HEADACHE AND PAIN (2018)
BOTULINUM NEUROTOXIN TYPE A-CLEAVED SNAP25 IS CONFINED TO PRIMARY MOTOR NEURONS AND LOCALIZED ON THE PLASMA MEMBRANE FOLLOWING INTRAMUSCULAR TOXIN INJECTION
Brian B. Cai et al.
NEUROSCIENCE (2017)
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Marco Pirazzini et al.
PHARMACOLOGICAL REVIEWS (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
The Multifaceted Role of SNARE Proteins in Membrane Fusion
Jing Han et al.
FRONTIERS IN PHYSIOLOGY (2017)
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
Manjit Matharu et al.
CEPHALALGIA (2017)
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Pregnancy outcomes following exposure to onabotulinumtoxinA
Mitchell F. Brin et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons
Ewa Bomba-Warczak et al.
CELL REPORTS (2016)
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
Andrew M. Blumenfeld et al.
BMC NEUROLOGY (2015)
Increasing placebo responses over time in US clinical trials of neuropathic pain
Alexander H. Tuttle et al.
PAIN (2015)
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
Fayyaz Ahmed et al.
SPRINGERPLUS (2015)
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
Andrea Negro et al.
SPRINGERPLUS (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Stephen D. Silberstein et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
S. K. Aurora et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains
Rami Burstein et al.
CEPHALALGIA (2014)
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
H. -C. Diener et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Botox in the prevention of chronic migraine; comparing NICE criteria versus hull criteria for evaluating responder rate
H. Zafar et al.
JOURNAL OF HEADACHE AND PAIN (2014)
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
Modar Khalil et al.
JOURNAL OF HEADACHE AND PAIN (2014)
OnabotulinumtoxinA Successfully Used as Migraine Prophylaxis During Pregnancy: A Case Report
Andrew Y. Robinson et al.
MILITARY MEDICINE (2014)
Immunogenicity of botulinum toxins
Markus Naumann et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival
Lisheng Peng et al.
NATURE COMMUNICATIONS (2013)
Chronic Migraine: Epidemiology and Disease Burden
Aubrey N. Manack et al.
CURRENT PAIN AND HEADACHE REPORTS (2011)
A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine
Roger K. Cady et al.
HEADACHE (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study
Ninan T. Mathew et al.
HEADACHE (2009)
Refractory headache: Historical perspective, need, and purposes for an operational definition
Elliott A. Schulman et al.
HEADACHE (2008)
Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A
A. A. Rogozhin et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Interictal Dysfunction of a Brainstem Descending Modulatory Center in Migraine Patients
Eric A. Moulton et al.
PLOS ONE (2008)
Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine
Andrew M. Blumenfeld et al.
HEADACHE (2008)
Pharmacology of therapeutic botulinum toxin preparations
Dirk Dressler et al.
DISABILITY AND REHABILITATION (2007)
Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study
H-C Diener et al.
CEPHALALGIA (2007)
Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial
Stephen D. Silberstein et al.
HEADACHE (2007)
A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type a for migraine prophylaxis
Arthur H. Elkind et al.
JOURNAL OF PAIN (2006)
Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache:: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study
SD Silberstein et al.
CEPHALALGIA (2006)
SV2 is the protein receptor for botulinum neurotoxin A
M Dong et al.
SCIENCE (2006)
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial
SD Silberstein et al.
MAYO CLINIC PROCEEDINGS (2005)
Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache:: A randomized, double-blind, placebo-controlled trial
NT Mathew et al.
HEADACHE (2005)
Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy
PL Durham et al.
HEADACHE (2004)
The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity
TJ Steiner et al.
CEPHALALGIA (2003)
Botulinum toxin - Mechanisms of action and clinical use in spasticity
M Barnes
JOURNAL OF REHABILITATION MEDICINE (2003)
Botulinum toxin type A and EMG: A key to the understanding of chronic tension-type headaches?
JD Rollnik et al.
HEADACHE (2001)
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
WJ Binder et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2000)
Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study
JD Rollnik et al.
HEADACHE (2000)
Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins
MJ Welch et al.
TOXICON (2000)
Share Paper
